William E. Holtz
Of Counsel
William (Bill) Holtz is a seasoned life sciences and U.S. Food and Drug Administration (FDA) regulatory and policy strategist. He provides clients with practical advice on regulatory matters, drawing on years of experience both in private practice and as a regulator. Bill has deep knowledge of the health product regulatory environment, including medical product regulation, clinical research, product life cycle management, digital technologies, and compliance.
Prior to joining Foley, Bill served as a division director in FDA’s Center for Drug Evaluation and Research, Office of Medical Policy, where he managed a portfolio of regulatory health policy programs. Previously, Bill spent over two decades providing strategic FDA regulatory development and policy consulting for biotechnology, medical device, and health care technology companies.
William Holtz Examines New FDA Approach to Clinical Trial Development
FDA Medical Devices: Important Regulatory Considerations for Companies Seeking to Enter the U.S. Market
William Holtz Quoted on Potential Regulatory Shifts for Peptide Compounding
William Holtz on Regulatory Balance in Peptide Market
FDA to Consider Lifting Restrictions on Numerous Compounded Peptides
